Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Mousa

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|March 16, 2001
Role of antiplatelet agents in strokeS A Mousa
Acta Chirurgica Belgica|July 16, 2005
Emerging links between thrombosis, inflammation and cancer: role of heparinS A Mousa
Seminars in Thrombosis and Hemostasis|September 30, 2000
Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disordersS A Mousa
American Journal of Physiologic Imaging|January 1, 1991
Animal models in radiotracer design of a Tc-labelled myocardial perfusion imaging agentS A Mousa
International Angiology : a Journal of the International Union of Angiology|March 8, 2006
Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparinS A Mousa
Hamostaseologie|January 6, 2006
Antithrombotics in thrombosis and cancerS A Mousa
International Angiology : a Journal of the International Union of Angiology|September 15, 2005
Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparinS A Mousa
Molecular Medicine Today|April 1, 1996
Angiogenesis promoters and inhibitors: potential therapeutic implicationsS A Mousa
Expert Opinion on Investigational Drugs|June 27, 2001
IBC's 6th Annual Conference on Angiogenesis: Novel Therapeutic DevelopmentsS A Mousa
Expert Opinion on Investigational Drugs|July 5, 2005
Cell adhesion molecules and extracellular matrix proteins: potential therapeutic applicationsS A Mousa
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Current Opinion in Investigational Drugs (London, England : 2000)|March 16, 2001
Role of antiplatelet agents in strokeS A Mousa
Acta Chirurgica Belgica|July 16, 2005
Emerging links between thrombosis, inflammation and cancer: role of heparinS A Mousa
Seminars in Thrombosis and Hemostasis|September 30, 2000
Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disordersS A Mousa
American Journal of Physiologic Imaging|January 1, 1991
Animal models in radiotracer design of a Tc-labelled myocardial perfusion imaging agentS A Mousa
International Angiology : a Journal of the International Union of Angiology|March 8, 2006
Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparinS A Mousa
Hamostaseologie|January 6, 2006
Antithrombotics in thrombosis and cancerS A Mousa
International Angiology : a Journal of the International Union of Angiology|September 15, 2005
Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparinS A Mousa
Molecular Medicine Today|April 1, 1996
Angiogenesis promoters and inhibitors: potential therapeutic implicationsS A Mousa
Expert Opinion on Investigational Drugs|June 27, 2001
IBC's 6th Annual Conference on Angiogenesis: Novel Therapeutic DevelopmentsS A Mousa
Expert Opinion on Investigational Drugs|July 5, 2005
Cell adhesion molecules and extracellular matrix proteins: potential therapeutic applicationsS A Mousa
Pageof 14